A clinical-stage pharmaceutical company developing best-in-class therapeutics designed to prevent and treat the toxic effects of heavy metal exposure ​on ​human health.

We are addressing the urgent need for safer, more effective solutions for heavy metal toxicity. Our orally-administered chelating agents are designed to simplify treatment for patients exposed to radioactive materials like uranium and plutonium, as well as environmental toxins such as lead, mercury, and other heavy metals. With a world-class team backed by over 20 years of funding​ ​from, and partnership with, the U.S. government, we are advancing our vision of a future without heavy metal poisoning.